Amelioration of Mugwort on the Obesity and Dyslipidemia Induced by High-Fat Diet

Min-Ah Kim¹, Kye Won Park² and Mi-Ja Kim^1,

¹Department of Food and Nutrition, College of Health Science, Kangwon National University, Samcheok, Gangwon 25949, Korea

²Department of Food Science and Biotechnology, Sungkyunkwan University, Suwon 16419, Korea

Cite this paper:
Min-Ah Kim, Kye Won Park and Mi-Ja Kim. Amelioration of Mugwort on the Obesity and Dyslipidemia Induced by High-Fat Diet. Journal of Food and Nutrition Research. 2019; 7(10):736-741. doi: 10.12691/jfnr-7-10-7

Abstract

Anti-obesity effects of Mugwort were evaluated in high fat diet-induced obesity mice models through determining physical changes and gene expression levels. High fat diet (HFD) models fed with 1% or 3% Mugwort had significantly lower body weight gain and food intake than HFD group (p<0.05). Especially, body weight gain and food intake of 3% Mugwort fed groups significantly decreased by 48.5% and 25.8%, respectively, compared to HFD group. In addition, parameters in plasma including LDL levels, concentration of plasma triglyceride and total cholesterol as well as histological changes in the liver were reduced in Mugwort supplemented groups compared to the HFD. Addition of Mugwort decreased the gene expression levels of epididymal adipose tissue genes including ACC, GPDH, and PPARγ. Therefore, Mugwort supplementation may participate in regulating plasma and hepatic steatosis as well as down-regulating adipogenic target gene expression.

Keywords:
Mugwort steatosis fat accumulated genes anti-obesity

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Funahashi, T. and Matsuzawa, Y., “Metabolic syndrome: Clinical concept and molecular basis”, Annals of Medicine, 39, 482-494, 2007.
[2]	Lautt, W.W., “A new paradigm for diabetes and obesity: The hepatic insulin sensitizing substance (HISS) hypothesis”, Journal of Pharmacological Sciences, 95, 9-17, 2004.
[3]	Hofbauer, K.G., Nicholson, J.R. and Boss, O., “The obesity epidemic: Current and future pharmacological treatments”, Annual Review of Pharmacology and Toxicology, 47, 565-592, 2007.
[4]	Tontonoz, P., Hu, E. and Spiegelman, B.M., “Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor”, Cell, 79, 1147-1156, 1994.
[5]	Zhao, X.Y., Chen, X.Y., Zhang, Z.J., Kang, Y., Liao, W.M., Yu, W.H. and Xiang, A.P., “Expression patterns of transcription factor PPARγ and C/EBP family members during in vitro adipogenesis of human bone marrow mesenchymal stem cells”, Cell Biology International, 39(4), 457-465, 2015.
[6]	Wu, Z., Puigserver, P. and Spiegelman, B.M., “Transcriptional activation of adipogenesis”, Current Opinion in Cell Biology, 11, 689-694, 1999.
[7]	Kim, M.J., Jeon, J. and Lee, J.S., “Fucoidan prevents high-fat diet-induced obesity in animals by suppression of fat accumulation”, Phytotheraphy Research, 28, 137-143, 2014.
[8]	Swierczynski, J., Zabrocka, L., Goyke, E., Raczynska, S., Adamonis, W. and Sledzinski, Z., “Enhanced glycerol 3-phosphate dehydrogenase activity in adipose tissue of obese humans”, Molecular and Cellular Biochemistry, 254, 55-59, 2003.
[9]	Andersen, C., Rayalam, S., Della-Fera, M.A. and Baile, C.A., “Phytochemicals and adipogenesis”, Biofactors, 36, 415-422, 2010.
[10]	Mayer, M.A., Höcht, C., Puyó, A. and Taira, C.A., “Recent advances in obesity pharmacotherapy”, Current Clinical Pharmacology, 4, 53-61, 2009.
[11]	Wang, S., Moustaid-Moussa, N., Chen, L., Mo, H., Shastri, A., Su, R., Bapat, P., Kwun, I. and Shen, C.L., “Novel insights of dietary polyphenols and obesity”, The Journal of Nutritional Biochemistry, 25, 1-18, 2014.
[12]	Bora, K.S. and Sharma, A., “The genus artemisia: A comprehensive review”, Pharmaceutical Biology, 49(1), 101-109, 2011.
[13]	Abad, M.J., Bedoya, L.M., Apaza, L., Bermejo, P., “The artemisia L. Genus: A review of bioactive essential oils”, Molecules, 17(3), 2542-2566, 2012.
[14]	Wink, M., “Plant breeding, importance of plant secondary metabolites for protection against pathogens and herbivores”, Theoretical and Applied Genetics, 75, 225-233, 1988.
[15]	Yun, K.W., Kil, B.S. and Han, D.M., “Phytotoxic and antimicrobial activity of volatile constituents of artemisia princeps var. orientalis”, Journal of Chemical Ecology, 19, 2757-2766, 1993.
[16]	Hwang, K.E., Choi, Y.S., Choi, J.H., Kim, H.Y., Lee, M.A., Kim, H.W., Chung, H.K. and Kim, C.J., “The antioxidative properties of Ganghwayak ssuk (artemisia princeps pamp.) extracts added to refrigerated raw chicken nugget batter against lipid oxidation”, Korean Journal for Food Science of Animal Resources, 31, 166-175, 2011.
[17]	Jang, W.S., Kim, Y.S. and Seol, I.C., Antioxidant and lipid-lowering effects of artemisia capillaris on a rat model of hyperlipidemia. The Journal of Korean Oriental Medicine, 33(2), 11-24, 2012.
[18]	Liu, L., Zhao, J., Li,Y., Wan, Y., Lin, J., Shen, A., Xu, W., Li, H., Zhang, Y., Xu, J., Peng, J. and Hong, Z., “Artemisia capillaris formula inhibits hepatic steatosis via an miR‑122‑induced decrease in fatty acid synthase expression in vivo and in vitro. Molecular Medicine Reports, 13(6), 4751-4758, 2016.
[19]	Badoni, R., Semwal, D.K. and Rawat, U., “Composition variation in essential oils of artemisia nilagirica and artemisia capillaris, growing in India. Journal of Applied and Natural Science, 2(1), 30-33, 2010.
[20]	Gaoa, Q., Zhaoa, X., Yin, L., Zhang, Y., Wang, B., Wu, X., Zhang, X., Fu, X. and Sun, W., “The essential oil of artemisia capillaris protects against CCl4-induced liver injury in vivo”, Revista Brasileira de Farmacognosia, 26, 369-374, 2016.
[21]	Sato, A., Kawano, H., Notsu, T., Ohta, M., Nakakuki, M., Mizuguchi, K., Itoh, M., Suganami, T. and Ogawa, Y., “Anti-obesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: Importance of hepatic lipogenesis”, Diabetes, 59, 2495-2504, 2010.
[22]	Rosen, E.D. and Spiegelman, B.M., “Adipocytes as regulators of energy balance and glucose homeostasis”, Nature, 444, 847- 853, 2006.
[23]	Shulman, G.I., “Cellular mechanisms of insulin resistance”, Journal of Clinical Investigation, 106, 171-176, 2000.
[24]	Guilherme, A., Virbasius, J.V., Puri, V. and Czech, M.P., “Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes”, Nature Reviews Molecular Cell Biology, 9(5), 367-377, 2008.
[25]	Perseghin, G., Scifo, P., De Cobelli, F., Pagliato, E., Battezzati, A., Arcelloni, C., Vanzulli, A., Testolin, G., Pozza, G., Del Maschio, A. and Luzi, L., “Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: A 1H–13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents”, Diabetes, 48, 1600 -1606, 1999.
[26]	Gauthier, M.S., Couturier, K., Latour, J.G. and Lavoie, J.M., “Concurrent exercise prevents high-fat-diet-induced macrovesicular hepatic steatosis”, Journal of Applied Physiology, 94, 2127-2134, 2003.
[27]	Staiger, H. and Häring, H.U., “Adipocytokines: Fat-derived humoral mediators of metabolic homeostasis”, Experimental and Clinical Endocrine and Diabetes, 113, 67-79, 2005.
[28]	Kim, D.W., Cho, H.I., Kim, K.M., Kim, S.J., Choi, J.S., Kim, Y.S. and Lee, S.M., “Isorhamnetin-3-O-galactoside protects against CCl4-Induced hepatic injury in mice”, Biomolecules and Therapeutics, 20(4), 406-412, 2012.
[29]	Rosen, E.D., Walkey, C.J., Puigserver, P. and Spiegelman, B.M., “Transcriptional regulation of adipogenesis”, Genes and Development, 14, 1293-1307, 2000.
[30]	Schoonjans, K., Staels, B. and Auwerx, J., “The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation”, Biochimica et Biophysica Acta, 1302, 93-109, 1996.
[31]	Kliewer, S.A. and Willson, T.M., “The nuclear receptor PPARγ-bigger than fat”, Current Opinion in Genetics and Development, 8, 576-581, 1998.
[32]	Furuhashi, M., Fucho, R., Görgün, C.Z., Tuncman, G., Cao, H. and Hotamisligil, G.S., “Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice”, Journal of Clinical Investigation, 118(7), 2640-2650, 2008.
[33]	Tong, L., “Acetyl-coenzyme A carboxylase: Crucial metabolic enzyme and attractive target for drug discovery”, Cellular and Molecular Life Sciences, 62, 1784-1803, 2005.
[34]	Moustaïd, N., Jones, B.H. and Taylor, J.W., “Insulin increases lipogenic enzyme activity in human adipocytes in primary culture”, Journal of Nutrition, 126, 865-870, 1996.